in a nutshell
On 22 December 2022, the Court of Justice of the European Union (CJEU) ruled on case C-530/20 concerning the interpretation of Articles 86, 87 and 90 of Directive 2001/83/EC on advertising (the “Directive”). I went down. Manufacture of pharmaceuticals for humans.
In this regard, the CJEU noted that the dissemination of information encouraging price-based drug purchases has declined, such as when a Latvian company offered a percentage reduction in the selling price of any drug if three additional products were purchased. made it clear that Within the definition of “pharmaceutical advertising”.
Furthermore, the CJEU has interpreted Article 87 of the Directive by recognizing the prerogative of Member States to prohibit elements that may encourage the unreasonable use of medicines in the advertising of non-prescription and non-reimbursed medicines. . Economic criteria related to price are so influential in the aforementioned categories of drugs that objective assessment of both the therapeutic properties of the drug and the medical needs of the patient may be overlooked. These elements also apply to combined sales.